BACKGROUND: In the present case study, after strict screening by the Research Center of Stem Cell Clinical Transformation Engineering Technology of Gannan Medical University, School of Rehabilitation Medicine of Gannan Medical University, the first and third Affiliated Hospitals of Gannan Medical University, and Jiangsu RE-Stem Biotechnology Co., Ltd, 5 volunteers with cerebral palsy were accepted for adipose-derived mesenchymal stem cell (ADMSC) transplantation on the premise that the subjects fully understood the terms and conditions of the study. We describe the cases of 5 participants who received intravenous infusions of ADMSCs. CLINICAL PRESENTATION: A total of 5 study participants received ADMSCs intravenously every 14 days, following a routine physical examination, and 3 infusions was considered 1 course of treatment. Routine rehabilitation training was concurrently provided and the participants were followed for 6 months to 1 year. Following treatment, scores for the gross motor function measure-88 (GMFM-88), the comprehensive functional assessment for children with cerebral palsy, and the fine motor function measure (FMFM) were improved. One of the study participants with a prior history of tuberculous pleurisy had a recurrence during treatment, but the symptoms disappeared with the appropriate medical intervention. Routine blood parameters of the other four participants were normal. CONCLUSIONS: After intravenous injection of ADMSCs, motor function and speech function improved in children with cerebral palsy, particularly in children with severe cerebral palsy. No obvious safety concerns were observed; however, further study is warranted. In addition, long-term follow-up and observational reports with large patients’ samples and multiple centers are still needed.